[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 4 (Autumn 2023) ::
Caspian J Intern Med 2023, 14(4): 687-693 Back to browse issues page
Non-inferiority of reverse hybrid regimen compared to standard concomitant regimen for H. pylori eradication in a randomized controlled trial
Seyed Mohammad Valizadeh Toosi , Vahid Hosseini , Hajar Shokri-Afra , Iradj Maleki *
Non-communicable Diseases Institute, Gut and Liver Research Center, Imam Khomeini Hospital, Sari, Iran , IMaleki@mazums.ac.ir
Abstract:   (424 Views)
Background: Helicobacter pylori (H. pylori) infection is strongly related to peptic ulcer disease, chronic gastritis, and gastric malignancies. Therefore, H. pylori eradication is necessary in these cases. This study was aimed to compare the efficacy of 14-day reverse hybrid therapy with standard 14-day concomitant regimen for H. pylori eradication in Iran.
Methods: Of the 317 patients with dyspepsia and H. pylori infection enrolled in the study, 153 and 164 patients were randomly assigned to reverse hybrid and concomitant groups, respectively. The reverse hybrid regimen containing pantoprazole, amoxicillin, clarithromycin, and metronidazole was taken every 12 hours in the first 7 days, however, Clarithromycin and Metronidazole were discontinued within the next 7 days. Patients in the concomitant group also received the same drugs for 14-day. Eradication confirmation tests were used 8 weeks after the end of treatments.
Results: A crowd of 281 patients continued the trial until the end. H. pylori eradication rates based on intention to treat analysis were 71.2% (109/153) and 83.5% (137/164) in reverse hybrid and concomitant groups, respectively (P = 0.007). By the per-protocol analysis, rates of eradication were 85.8% (109/127) and 89% (137/154), respectively (P = 0.428). Severe side effects were few in both groups. More side effects were observed in concomitant group (p < 0.001), however, the severity of side effects was not statistically different between the two regimens (P = 0.314). Reverse hybrid regimen was better tolerated (98% vs. 91.5%, P= 0.009).
Conclusion: Both 14-day reverse hybrid and concomitant regimens have a fair response rate in Iran.

Keywords: Concomitant, Eradication regimens, Helicobacter pylori infection, Reverse hybrid, Randomized controlled trial
Full-Text [PDF 721 kb]   (230 Downloads)    
Type of Study: Original Article | Subject: Gastroentrology
Received: 2022/07/2 | Accepted: 2022/09/13 | Published: 2023/09/28
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Valizadeh Toosi S M, Hosseini V, Shokri-Afra H, Maleki I. Non-inferiority of reverse hybrid regimen compared to standard concomitant regimen for H. pylori eradication in a randomized controlled trial. Caspian J Intern Med 2023; 14 (4) :687-693
URL: http://caspjim.com/article-1-3550-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 4 (Autumn 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4624